Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Harvard Business School
AstraZeneca
Dow

Last Updated: March 26, 2023

Investigational Drug Information for LGX818


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug LGX818?

LGX818 is an investigational drug.

There have been 31 clinical trials for LGX818. The most recent clinical trial was a Phase 2 trial, which was initiated on December 21st 2020.

The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Neoplasms. The leading clinical trial sponsors are Array BioPharma, Pfizer, and National Cancer Institute (NCI).

There are two hundred and thirty US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for LGX818
TitleSponsorPhase
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationNational Cancer Institute (NCI)Phase 2
BRAF V600E-mutant and MSI-H Metastatic Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus Pembrolizumab Compared to Pembrolizumab AloneEli Lilly and CompanyPhase 2
BRAF V600E-mutant and MSI-H Metastatic Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus Pembrolizumab Compared to Pembrolizumab AloneMerck KGaA, Darmstadt, GermanyPhase 2

See all LGX818 clinical trials

Clinical Trial Summary for LGX818

Top disease conditions for LGX818
Top clinical trial sponsors for LGX818

See all LGX818 clinical trials

US Patents for LGX818

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LGX818 See Plans and Pricing Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO) See Plans and Pricing
LGX818 See Plans and Pricing Small molecule HSP70 inhibitors The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA) See Plans and Pricing
LGX818 See Plans and Pricing Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH) See Plans and Pricing
LGX818 See Plans and Pricing Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) See Plans and Pricing
LGX818 See Plans and Pricing 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof Samumed, LLC (San Diego, CA) See Plans and Pricing
LGX818 See Plans and Pricing Aerosol pirfenidone and pyridone analog compounds and uses thereof AVALYN PHARMA INC. (Seattle, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LGX818

Drugname Country Document Number Estimated Expiration Related US Patent
LGX818 Argentina AR077975 2029-08-28 See Plans and Pricing
LGX818 Australia AU2010286569 2029-08-28 See Plans and Pricing
LGX818 Brazil BR112012004453 2029-08-28 See Plans and Pricing
LGX818 Canada CA2771775 2029-08-28 See Plans and Pricing
LGX818 Chile CL2012000340 2029-08-28 See Plans and Pricing
LGX818 China CN102725283 2029-08-28 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Harvard Business School
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.